Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VIVA

维亚生物科技控股集团

VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

POSITIVE PROFIT ALERT

This announcement is made by Viva Biotech Holdings (the "**Company**", together with its subsidiaries, collectively referred to as the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company ("**Shareholders**") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2024 (the "**Year**") and information currently available, the Group expects to record a turnaround and post a net profit for the Year in the range of RMB210 million to RMB240 million and net profit attributable to the Shareholders in the range of RMB150 million to RMB180 million for the Year as compared with a net loss of RMB99.8 million for the year ended December 31, 2023 (the "**FY2023**") and a net loss attributable to the Shareholders of RMB116.1 million for FY2023. The Group expects that the adjusted non-International Financial Reporting Standards ("**non-IFRS**") net profit and a net profit attributable to the Shareholders for the Year (after excluding the one off restructuring expenses, impairment losses on property, plant and equipment, subsidiary's share incentive expenses and amortization of acquired assets) will be in the range of RMB300 million to RMB330 million and RMB240 million to RMB270 million, respectively, such increase was mainly attributable to substantial growth recovery of contract research organization (CRO) business in the second half of the Year, higher operating margins resulting from improved operational efficiency, as well as investment gains recognized from milestone payments received by the Group during the Year.

The Company is in the process of preparing the audited consolidated financial results of the Group for the Year. The information contained in this announcement is based on a preliminary assessment of the unaudited consolidated management accounts currently available to the Company, which is subject to finalization and other potential adjustments (if any) and has not been audited or reviewed by the Company's auditors or the audit committee of the Company. The actual results of the Group for the Year may differ from the information contained in this announcement. Details of the Group's performance will be disclosed in the annual results announcement of the Company for the Year, which is expected to be published by the end of March 2025.

The Company believes that the above adjusted Non-IFRS financial measures are useful for understanding and assessing underlying business performance and operating trends of the Company by the Company's management and investors, and that the Company's management and investors may benefit from referring to these adjusted financial measures in assessing the Group's financial performance by eliminating the impact of certain unusual and non-recurring items that the Group does not consider indicative of the performance of the Group's business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the International Financial Reporting Standards ("IFRS"). You should not view the adjusted results on a stand-alone basis or as a substitute for results under the IFRS. Shareholders and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong
March 13, 2025

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. WU Ying and Mr. Ren Delin; two Non-executive Directors, namely, Mr. WU Yuting and Mr. Wang Stephen Hui; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.